Fibroblast activation protein and disease severity, progression and survival in IPF

T S Prior; N Hoyer; Jesper Rømhild Davidsen; S B Shaker; B W Deleuran; E Bendstrup; T W Kragstrup

doi:10.1183/13993003.congress-2022.510

Fibroblast activation protein and disease severity, progression and survival in IPF

T S Prior, N Hoyer, Jesper Rømhild Davidsen, S B Shaker, B W Deleuran, E Bendstrup, T W Kragstrup

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

Abstract

Background: Fibroblast activation protein alpha (FAP) is a blood biomarker of activated fibroblasts and may be associated with disease severity in idiopathic pulmonary fibrosis (IPF). We aimed to examine the association between FAP and disease characteristics in patients with IPF.Methods: Baseline serum levels of FAP were measured by ELISA (RayBiotech) in patients with IPF followed for up to 3 years with collection of clinical data (pulmonary function and exercise capacity), quality of life (QoL by King’s Brief Interstitial lung disease questionnaire and IPF-specific Saint George’s Respiratory questionnaire), disease progression (FVC gt;10% or DLCO gt;15 and survival.Results: Among 149 included patients, median baseline FAP was 50 ng/ml (range 18-205). No significant associations with baseline FVC, DLCO, 6-min walk test, gender-age-physiology index, QoL, disease progression (all pgt;0.05) or survival (HR 0.996, 95 0.984-1.001) were found.Analyses of patients with FAP above or below 70 ng/ml (mean FAP + 2*SD of healthy controls) showed lower FVC during follow-up in patients with high FAP at baseline (plt;0.01). There was no association with baseline parameters (pgt;0.05), survival (HR 0.94, 95 0.50-1.79) or progression-free survival (HR 0.88, 95 0.51-1.52).Conclusion: Baseline FAP is only weakly associated with disease progression in patients with IPF limiting its use as a biomarker for clinical application.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 510.This article was presented at the 2022 ERS International Congress, in session textquotedblleft-textquotedblright.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

Originalsprog	Engelsk
Tidsskrift	European Respiratory Journal
Vol/bind	60
Nummer	suppl 66
ISSN	0903-1936
DOI	https://doi.org/10.1183/13993003.congress-2022.510
Status	Udgivet - 2022

Adgang til dokumentet

10.1183/13993003.congress-2022.510

https://erj.ersjournals.com/content/60/suppl_66/510

Citationsformater

@article{0ff317080e9b4e058a33252e79792514,

title = "Fibroblast activation protein and disease severity, progression and survival in IPF",

abstract = "Background: Fibroblast activation protein alpha (FAP) is a blood biomarker of activated fibroblasts and may be associated with disease severity in idiopathic pulmonary fibrosis (IPF). We aimed to examine the association between FAP and disease characteristics in patients with IPF.Methods: Baseline serum levels of FAP were measured by ELISA (RayBiotech) in patients with IPF followed for up to 3 years with collection of clinical data (pulmonary function and exercise capacity), quality of life (QoL by King{\textquoteright}s Brief Interstitial lung disease questionnaire and IPF-specific Saint George{\textquoteright}s Respiratory questionnaire), disease progression (FVC gt;10% or DLCO gt;15 and survival.Results: Among 149 included patients, median baseline FAP was 50 ng/ml (range 18-205). No significant associations with baseline FVC, DLCO, 6-min walk test, gender-age-physiology index, QoL, disease progression (all pgt;0.05) or survival (HR 0.996, 95 0.984-1.001) were found.Analyses of patients with FAP above or below 70 ng/ml (mean FAP + 2*SD of healthy controls) showed lower FVC during follow-up in patients with high FAP at baseline (plt;0.01). There was no association with baseline parameters (pgt;0.05), survival (HR 0.94, 95 0.50-1.79) or progression-free survival (HR 0.88, 95 0.51-1.52).Conclusion: Baseline FAP is only weakly associated with disease progression in patients with IPF limiting its use as a biomarker for clinical application.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 510.This article was presented at the 2022 ERS International Congress, in session textquotedblleft-textquotedblright.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).",

author = "Prior, {T S} and N Hoyer and Davidsen, {Jesper R{\o}mhild} and Shaker, {S B} and Deleuran, {B W} and E Bendstrup and Kragstrup, {T W}",

year = "2022",

doi = "10.1183/13993003.congress-2022.510",

language = "English",

volume = "60",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "suppl 66",

}

TY - JOUR

T1 - Fibroblast activation protein and disease severity, progression and survival in IPF

AU - Prior, T S

AU - Hoyer, N

AU - Davidsen, Jesper Rømhild

AU - Shaker, S B

AU - Deleuran, B W

AU - Bendstrup, E

AU - Kragstrup, T W

PY - 2022

Y1 - 2022

N2 - Background: Fibroblast activation protein alpha (FAP) is a blood biomarker of activated fibroblasts and may be associated with disease severity in idiopathic pulmonary fibrosis (IPF). We aimed to examine the association between FAP and disease characteristics in patients with IPF.Methods: Baseline serum levels of FAP were measured by ELISA (RayBiotech) in patients with IPF followed for up to 3 years with collection of clinical data (pulmonary function and exercise capacity), quality of life (QoL by King’s Brief Interstitial lung disease questionnaire and IPF-specific Saint George’s Respiratory questionnaire), disease progression (FVC gt;10% or DLCO gt;15 and survival.Results: Among 149 included patients, median baseline FAP was 50 ng/ml (range 18-205). No significant associations with baseline FVC, DLCO, 6-min walk test, gender-age-physiology index, QoL, disease progression (all pgt;0.05) or survival (HR 0.996, 95 0.984-1.001) were found.Analyses of patients with FAP above or below 70 ng/ml (mean FAP + 2*SD of healthy controls) showed lower FVC during follow-up in patients with high FAP at baseline (plt;0.01). There was no association with baseline parameters (pgt;0.05), survival (HR 0.94, 95 0.50-1.79) or progression-free survival (HR 0.88, 95 0.51-1.52).Conclusion: Baseline FAP is only weakly associated with disease progression in patients with IPF limiting its use as a biomarker for clinical application.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 510.This article was presented at the 2022 ERS International Congress, in session textquotedblleft-textquotedblright.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

AB - Background: Fibroblast activation protein alpha (FAP) is a blood biomarker of activated fibroblasts and may be associated with disease severity in idiopathic pulmonary fibrosis (IPF). We aimed to examine the association between FAP and disease characteristics in patients with IPF.Methods: Baseline serum levels of FAP were measured by ELISA (RayBiotech) in patients with IPF followed for up to 3 years with collection of clinical data (pulmonary function and exercise capacity), quality of life (QoL by King’s Brief Interstitial lung disease questionnaire and IPF-specific Saint George’s Respiratory questionnaire), disease progression (FVC gt;10% or DLCO gt;15 and survival.Results: Among 149 included patients, median baseline FAP was 50 ng/ml (range 18-205). No significant associations with baseline FVC, DLCO, 6-min walk test, gender-age-physiology index, QoL, disease progression (all pgt;0.05) or survival (HR 0.996, 95 0.984-1.001) were found.Analyses of patients with FAP above or below 70 ng/ml (mean FAP + 2*SD of healthy controls) showed lower FVC during follow-up in patients with high FAP at baseline (plt;0.01). There was no association with baseline parameters (pgt;0.05), survival (HR 0.94, 95 0.50-1.79) or progression-free survival (HR 0.88, 95 0.51-1.52).Conclusion: Baseline FAP is only weakly associated with disease progression in patients with IPF limiting its use as a biomarker for clinical application.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 510.This article was presented at the 2022 ERS International Congress, in session textquotedblleft-textquotedblright.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

U2 - 10.1183/13993003.congress-2022.510

DO - 10.1183/13993003.congress-2022.510

M3 - Journal article

SN - 0903-1936

VL - 60

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - suppl 66

ER -

Fibroblast activation protein and disease severity, progression and survival in IPF

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater